Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.

Paton, D M

Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine. [electronic resource] - Drugs of today (Barcelona, Spain : 1998) Oct 2019 - 605-613 p. digital

Publication Type: Journal Article; Review

1699-3993

10.1358/dot.2019.55.10.3030645 doi


Antibodies, Monoclonal--pharmacology
Antibodies, Monoclonal, Humanized--pharmacology
Drug Approval
Humans
Interleukin-23 Subunit p19--antagonists & inhibitors
Psoriasis--therapy
Treatment Outcome
United States
United States Food and Drug Administration